Scholar Rock (SRRK) Competitors $33.12 +0.47 (+1.44%) Closing price 04:00 PM EasternExtended Trading$33.12 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRRK vs. VTRS, RDY, ASND, QGEN, MRNA, BBIO, ELAN, VRNA, ROIV, and GRFSShould you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Scholar Rock vs. Its Competitors Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S QIAGEN Moderna BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Grifols Viatris (NASDAQ:VTRS) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Is VTRS or SRRK more profitable? Scholar Rock has a net margin of 0.00% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Viatris-24.57% 16.54% 7.06% Scholar Rock N/A -127.11%-90.09% Do analysts recommend VTRS or SRRK? Viatris currently has a consensus price target of $10.40, indicating a potential downside of 1.52%. Scholar Rock has a consensus price target of $45.75, indicating a potential upside of 38.13%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts clearly believe Scholar Rock is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Does the media prefer VTRS or SRRK? In the previous week, Viatris and Viatris both had 3 articles in the media. Scholar Rock's average media sentiment score of 1.76 beat Viatris' score of 0.12 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Scholar Rock 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals & insiders believe in VTRS or SRRK? 79.9% of Viatris shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, VTRS or SRRK? Viatris has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Which has higher earnings & valuation, VTRS or SRRK? Scholar Rock has lower revenue, but higher earnings than Viatris. Scholar Rock is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.84-$634.20M-$2.90-3.64Scholar Rock$33.19M95.93-$246.29M-$2.91-11.38 SummaryScholar Rock beats Viatris on 10 of the 16 factors compared between the two stocks. Get Scholar Rock News Delivered to You Automatically Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRRK vs. The Competition Export to ExcelMetricScholar RockMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.18B$3.10B$5.69B$9.68BDividend YieldN/A2.28%6.66%4.54%P/E Ratio-11.3820.9982.6526.40Price / Sales95.93207.75454.15178.36Price / CashN/A43.5325.7028.92Price / Book8.419.8811.246.06Net Income-$246.29M-$53.38M$3.28B$266.05M7 Day Performance-1.95%-0.14%0.15%-0.07%1 Month Performance-8.91%9.18%8.34%5.83%1 Year Performance256.13%7.53%54.21%17.88% Scholar Rock Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRRKScholar Rock4.4972 of 5 stars$33.12+1.4%$45.75+38.1%+251.1%$3.18B$33.19M-11.38140News CoveragePositive NewsVTRSViatris1.8394 of 5 stars$10.55-0.9%$10.40-1.4%-12.7%$12.42B$14.74B-3.6432,000RDYDr. Reddy's Laboratories2.6452 of 5 stars$14.46-0.4%$16.95+17.3%-15.0%$12.11B$3.81B21.9027,811News CoveragePositive NewsASNDAscendis Pharma A/S3.4507 of 5 stars$190.37-2.0%$243.36+27.8%+40.3%$11.89B$393.54M-36.891,017News CoveragePositive NewsAnalyst ForecastQGENQIAGEN4.1632 of 5 stars$48.92-1.6%$49.69+1.6%+4.7%$11.06B$1.98B28.905,765News CoverageMRNAModerna4.548 of 5 stars$25.35-6.5%$42.88+69.2%-68.9%$10.55B$3.24B-3.375,800BBIOBridgeBio Pharma4.057 of 5 stars$47.29-3.6%$61.35+29.7%+85.9%$9.38B$221.90M-11.56400Positive NewsELANElanco Animal Health2.8738 of 5 stars$17.80-0.6%$17.33-2.6%+18.8%$8.90B$4.48B20.709,000VRNAVerona Pharma PLC American Depositary Share2.3168 of 5 stars$105.62+0.1%$109.00+3.2%+285.4%$8.64B$221.67M-106.6930News CoveragePositive NewsROIVRoivant Sciences3.0024 of 5 stars$11.64-2.3%$16.50+41.8%-2.5%$8.14B$29.05M-16.63860News CoveragePositive NewsAnalyst ForecastGRFSGrifols3.985 of 5 stars$9.82-3.3%$10.30+4.9%+6.7%$6.99B$7.81B8.3923,822News CoveragePositive NewsGap Down Related Companies and Tools Related Companies VTRS Competitors RDY Competitors ASND Competitors QGEN Competitors MRNA Competitors BBIO Competitors ELAN Competitors VRNA Competitors ROIV Competitors GRFS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRRK) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scholar Rock Holding Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Scholar Rock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
